Merck rolls out 3 new Keytruda prostate cancer studies by Carly Helfand Thursday, February 14, 2019 If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.
Big Keytruda win sets Merck up to steal BMS' kidney cancer share by Carly Helfand Tuesday, February 12, 2019 BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.
Novel pneumococcal vaccine enters human testing by Angus Liu Wednesday, February 13, 2019 In a phase 1/2 study, Astellas and Affinivax's MAPS-based vaccine will be tested head-to-head against Pfizer's Prevnar 13.
Merck's Keytruda nabs priority head and neck cancer review by Carly Helfand Monday, February 11, 2019 Merck’s Keytruda is duking it out with BMS' Opdivo in head and neck cancer, but Keytruda just took one step toward a big edge.
Big Pharma CEOs decide to show up at Senate pricing hearings by Eric Sagonowsky Wednesday, February 6, 2019 Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.
Point-of-care deal pairs Meredith content with Mesmerize network by Beth Snyder Bulik Thursday, February 7, 2019 Content is king, and it’s especially important in pharma. That’s why point-of-care agency Mesmerize has inked a deal with a top magazine publisher.
Merck analysts to CEO Frazier: What’s so great about the pipeline? by Arlene Weintraub Friday, February 1, 2019 Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.
Merck’s Prevnar challenger nabs FDA ‘breakthrough’ tag by Angus Liu Monday, February 4, 2019 Merck's 15-strain pneumococcal vaccine got an FDA breakthrough tag for children, months after Pfizer's 20-valent shot won one in adults.
Takeda’s dengue shot hits the mark in massive phase 3 study by Eric Sagonowsky Tuesday, January 29, 2019 Takeda's dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.
BMS, Roche will top burgeoning I-O market worth $29B: analyst by Angus Liu Monday, January 28, 2019 The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.